Drugs and patents in ATC class V08

Last updated: June 5, 2026

Executive summary

ATC V08 contrast media is dominated by iodinated small-molecule radiographic agents and gadolinium-based MR agents, with patent strategies split across (i) new molecular entities, (ii) formulation and imaging-performance improvements (high concentration, viscosity control, osmolality, stability, and shelf-life), and (iii) device-adjacent delivery formats (ready-to-use syringes, injectors, kits). Exclusivity is now governed less by broad “composition of matter” coverage for older products and more by secondary patents that persist at the formulation and manufacturing-process level, while regulatory reliance and bioequivalence standards for contrast media often keep generics in play once core protection expires. Paragraph IV challenges concentrate on liquid formulations, container/kit variants, and manufacturing steps that are not fully captured by early patents. Litigation is most likely where the Orange Book lists active patents for multiple dosage forms and where FDA approval pathways permit reliance on published literature rather than new clinical endpoints.

What patents protect ATC Class V08 contrast media products in the US?

Protection in V08 typically spans three layers: (1) active-ingredient composition claims for specific iodinated or gadolinium chelate molecules, (2) formulation patents tied to stability, osmolality, viscosity, chelate robustness, and sterilization/excipient systems, and (3) manufacturing process and sterilization claims. Delivery format patents can also matter, particularly for pre-filled syringes and pharmacy-batch vs. hospital-assembled kits.

Composition-of-matter vs formulation vs process: where exclusivity usually sits

Iodinated x-ray contrast media (small molecules): Core patents often cover specific iodinated chemical scaffolds and salt forms. Over time, “new formulation” patents become the principal barrier, especially those improving injectability at high concentration, reducing pain, or improving temperature stability.
Gadolinium-based MR contrast agents: Main protection frequently follows specific chelate frameworks and stability features that reduce free gadolinium risk. Secondary patents often address formulation stability (pH, buffering, chelating agent amounts), sterilization processes, and container compatibility.

Patent estate anatomy buyers look for

Across contrast media, the “effective barrier” is usually the most recent, Orange Book-listed patent family with enforceable claims that map to the FDA-labeled formulation and container:

Concentration and osmolality profiles aligned to the label
Stabilizing excipients and pH buffers
Water-of-injection standards and sterilization method
Container closure system compatibility (extractables/leachables can support formulation-specific claims)
Manufacturing controls affecting particle size, dissolution rate, or chelate integrity

How many patents cover iodinated x-ray contrast media and gadolinium MR contrast agents?

A defensible count requires knowing each FDA-listed product and its Orange Book families. Market-wide, V08 estates generally include multiple patent types per NDC:

older products may still show multiple listed patents but many expire quickly after initial composition protection
newer product launches often show a larger spread across formulation and process with later expirations

Without product-by-product Orange Book extraction, a numerical “how many patents” figure at class level cannot be stated without risking error.

When do major V08 contrast media products lose exclusivity in the US?

For many V08 products, the earliest composition patents expired years ago, shifting the exclusivity “front” to:

formulation patents tied to high concentration/low viscosity and improved stability
process patents for sterilization and batch manufacturing
use-related patents where the label includes a specific imaging protocol or dosing approach

Exclusivity timing is therefore product- and dosage-form specific. A class-level single expiration date is not meaningful because iodinated and gadolinium products have different filing timelines and patent families.

Which Paragraph IV challenges target contrast media formulations and delivery formats?

Paragraph IV litigation in V08 usually targets one or more of the following:

formulation variants (different concentration, different buffering system, or different excipient ratios)
container/kit variants (ready-to-use syringes, multi-dose vials, pharmacy bulk)
manufacturing process changes (sterilization conditions, purification steps, chelation stoichiometry controls)
manufacturing impurity profiles and specifications that are claim-relevant

Commercial impact is highest when the challenger seeks launch across multiple NDCs tied to the same label strength and container.

What is the Orange Book status of ATC V08 contrast media drugs?

Orange Book status differs by product and NDC. In general for contrast media:

branded reference products commonly list active patents for one or more strengths and dosage forms
generics often file under ANDA for small-molecule contrast media and must meet reference product quality standards
MR agents may show heavier formulation and process patent listings that can delay generic substitution even when chemical structures are not new

A complete Orange Book “status map” cannot be produced without enumerating the specific FDA reference products and their NDC-level listed patents.

How does ATC V08 contrast media patent strength compare across iodinated vs gadolinium agents?

Patent “strength” in practice typically tracks whether secondary patents survive and whether they are claim-mapped to the marketed formulation:

Iodinated agents: more likely to have multiple aging formulation patents still present for specific strengths. Competitive entry often hinges on demonstrating equivalence of excipient system and viscosity/osmolality characteristics.
Gadolinium agents: stronger linkage between chelate stability and safety can support durable formulation and process claims. Patent arguments may also involve whether the generic’s chelate stability and impurity profile achieve label-relevant performance.

What formulations are protected by V08 contrast media patents?

Common formulation claim targets include:

buffering systems and pH windows that stabilize the active ingredient
chelating agents and stoichiometric ratios (MR agents)
surfactants or tonicity modifiers affecting injectability and osmolality
viscosity control via excipient selection and concentration adjustments
sterilization and post-sterilization stability (including filtration and thermal treatment)
container compatibility including leachables from elastomers and glass/liner interactions

This formulation-centric landscape matters because contrast media approvals often rely on physicochemical equivalence even when the molecular scaffold is old.

What manufacturing/IP barriers block generic entry for contrast media?

Generic applicants frequently face barriers where claims cover:

purification steps producing a specific impurity spectrum
process parameters that are not fully disclosed in public files
sterilization method that changes stability and particle distributions
chelate formation conditions (for gadolinium) that affect residual free gadolinium and stability metrics
container fill and handling workflows supporting product quality

Even when composition patents expire, process claims can slow or deter launch if the generic cannot design around enforceable limitations.

What FDA pathways govern generic and biosimilar-style entry risk for V08?

Contrast media are typically approved via:

ANDA (small molecules) for iodinated contrast agents where an approved reference exists
ANDA for MR agents as chemically defined products (not biosimilars) In contrast media, “biosimilar risk” is generally not the right construct because these are not biologics. The risk profile is more about ANDA certification design-around and data/CMC equivalence.

How does ATC V08 competition evolve after patent expiry: timeline scenarios

A typical commercial and legal sequence for V08 in the US:

Patent expiry window: last active Orange Book patent(s) for the relevant NDC(s) approach expiration.
ANDA certification and litigation: Paragraph IV filings trigger automatic stay and district court litigation.
Settlement or final court decision: generic entry occurs if court affirms noninfringement or a settlement eliminates the dispute.
Launch execution: competition lands across one or more strengths and containers, with payer contracting often deciding uptake.

Because V08 includes multiple strengths and containers per product, entry is often staggered by NDC.

Which companies lead V08 contrast media and how does IP concentration map to their portfolios?

V08 leadership is concentrated among global branded manufacturers that maintain large portfolios of iodinated and gadolinium contrast agents and continue to file formulation/process improvements. However, producing a company-by-company IP concentration table requires enumerating each product reference in the Orange Book and mapping its assignees and continuation families.

What patent litigation affects contrast media generics most often?

Litigation themes include:

claim construction disputes over formulation/process limitations
CMC-specific infringement arguments tied to specs (impurities, chelate stability, viscosity, particle size)
design-around attempts using different excipient ratios, buffers, or sterilization parameters
secondary-use or protocol-related patents where imaging practice includes label-specific dosing instructions

The cases that matter commercially are those tied to NDCs with large market share and those that survive long enough to govern the first wave of generic approvals.

What settlement agreements drive generic launch for contrast media?

When settlements occur, they typically:

allow launch of generic at a defined time or after dismissal of select claims
include product-specific, formulation-specific design-around covenants
govern distribution with limited “launch curve” or restricted NDC coverage

A settlement “profile” cannot be stated accurately at class level without listing the specific litigated patents and the docket outcomes.

Revenue exposure: how much contrast media spend sits behind current patent barriers?

Class-level revenue exposure is not determinable here without:

a named product list
mapping each product to its active Orange Book patents and remaining term
linking to sales by strength and dosage form

V08 is too broad to produce a single monetizable estimate without risking material error.

Key differences: iodinated x-ray vs gadolinium MR contrast media IP strategies

Dimension	Iodinated x-ray contrast media (ATC V08)	Gadolinium-based MR contrast agents (ATC V08)
Core asset	Specific iodinated chemical scaffolds and salts	Specific chelate frameworks
Patent “hot zone”	Formulation for concentration, viscosity, osmolality; container stability	Chelate stability and residual metal control; formulation and sterilization
Generic barrier	ANDA design-around on excipients/buffers and process	ANDA design-around on stability, impurities, and process conditions
Litigation focus	Specs-based infringement (physicochemical)	Stability and chelate integrity related claim limitations
Biosimilar framing	Not applicable	Not applicable (not biologics)

How does V08 patent expiration risk differ by geography (US vs EU vs UK)?

For contrast media, key geographic differences stem from:

the scope of patent claims and prosecution history in each jurisdiction
regulatory exclusivity mechanisms distinct to each agency
patent term adjustments and supplementary protection certificate regimes for small molecules in EU

A geographic risk matrix requires identifying specific patent families and their countries. Class-level statements would be non-actionable.

Key Takeaways

V08 contrast media IP is typically formulation and process driven for older reference products, even when core compositions are long expired.
Competitive entry risk is highest where challengers can certify ANDA against the latest Orange Book-listed patents for the exact NDC/strength/container.
Paragraph IV challenges most often focus on liquid formulation equivalence and manufacturing/sterilization details that can be claim-relevant.
“Biosimilar risk” is generally not the right framing for V08 because these are chemically defined small molecules, not biologics.
Actionable diligence requires NDC-level Orange Book mapping and claim charting against formulation and process patents that match the marketed label and CMC specs.

FAQs

How do viscosity and osmolality specifications affect contrast media generic infringement?
What claim types most commonly survive in contrast media late-life patent estates?
How do container-fill and sterilization process differences show up in ANDA design-arounds for contrast media?
Which Orange Book listings are typically the longest tail for iodinated contrast agents vs gadolinium agents?
What settlement structures most often govern first-launch NDC scope for contrast media generics?

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
FDA. ANDA Regulatory Pathway Guidance. US Food and Drug Administration.
FDA. Paragraph IV Certification and Patent Certifications (ANDA). US Food and Drug Administration.
European Medicines Agency (EMA). Regulatory and legal framework for generic and biosimilar medicines (context for exclusivity and patent considerations).

Drugs in ATC Class V08

Subclasses in ATC: V08 - CONTRAST MEDIA

Patent Landscape and Market Dynamics for ATC Class V08 Contrast Media: Exclusivity, Generics, and Litigation Risk